Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Switch from fin to dut and its worse

      in Finasteride/Dutasteride  4 upvotes 1 year ago
      Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.

      community I had claude create a protocol only using fda approved drugs.

      in Research/Science  4 upvotes 6 months ago
      A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

      community RU58841 vs 2.5 mg Dutasterid ?

      in Research/Science  5 upvotes 3 months ago
      The conversation discusses the effectiveness of using 2.5 mg Dutasteride daily versus combining 0.5 mg Dutasteride with 150 mg RU58841 for reducing scalp DHT. Opinions vary, with some users recommending lower doses of Dutasteride and cautioning against RU58841 due to potential side effects.

      community Where to buy topical Adenosine?

      in Product  7 upvotes 3 years ago
      Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. User seeks where to buy topical Adenosine.

      community How. can I counteract the rapid hair loss caused by steroids?

      in Finasteride/Dutasteride  1 upvotes 1 year ago
      The conversation is about a person experiencing hair loss from steroid use, considering treatments like RU58841, dutasteride, and Nizoral, while avoiding finasteride and Minoxidil due to concerns about hormones and hypertension. The consensus suggests using dutasteride or finasteride, as Nizoral alone is not effective.